LG AI Research Partners with D&D Pharmatech for Oral Peptide Drug Discovery
LG AI Research and D&D Pharmatech have partnered to accelerate next-generation oral peptide drug discovery using advanced AI technologies. The collaboration aims to enhance drug development efficiency and strengthen LG’s leadership in the rapidly growing AI-driven biopharmaceutical market.
Oral Peptide Therapy | 18/06/2026 | By News Bureau
Johnson & Johnson Secures FDA Approval for Icotyde, First Oral IL-23 Inhibitor for Psoriasis
FDA approves Johnson & Johnson’s Icotyde, a first-in-class oral IL-23 receptor antagonist, offering a once-daily treatment option for moderate-to-severe plaque psoriasis in adults and adolescents.
Oral Peptide Therapy | 20/03/2026 | By News Bureau | 297
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy